Proehl Investment Ventures LLC 3
3 · Dermata Therapeutics, Inc. · Filed Aug 12, 2021
Insider Transaction Report
Form 3
Proehl Investment Ventures LLC
10% Owner
Holdings
- 917,317
Common Stock
Series 1d Preferred Stock
→ Common Stock (2,436,657 underlying)Series 1a Preferred Stock
→ Common Stock (2,295,000 underlying)Series 1b Preferred Stock
→ Common Stock (3,722,500 underlying)Series 1c Preferred Stock
→ Common Stock (25,582,050 underlying)Series 1 Preferred Stock
→ Common Stock (1,755,622 underlying)Series 1a Warrants
From: 2016-11-15Exp: 2026-03-14→ Common Stock (573,750 underlying)
Footnotes (7)
- [F1]Shares reported reflect the 1 for 20.5 stock split effected July 1, 2021 (the "Stock Split").
- [F2]The Series 1d Preferred Stock is convertible into shares of Common Stock at a conversion ratio equal to 80% of the offering price in connection with the Issuer's initial public offering ("IPO"). All shares of Series 1d Preferred Stock will be converted into 361,147 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split.
- [F3]The Series 1a Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1a Preferred Stock will be converted into 111,951 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split.
- [F4]The Series 1b Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1b Preferred Stock will be converted into 181,585 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split.
- [F5]The Series 1c Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1c Preferred Stock will be converted into 1,247,904 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split.
- [F6]The Series 1 Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1 Preferred Stock will be converted into 85,640 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split.
- [F7]The Series 1a Preferred Warrants are convertible into warrants to purchase Common Stock in connection with the Issuer's IPO. All Series 1a Preferred Warrants will be converted into warrants exercisable at $20.50 per share to purchase up to 27,987 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio and exercise price reflect the Stock Split.